Acadia Pharmaceuticals shares are trading higher Wednesday after the company won summary judgement in a patent suit. Just then Acadia Surged upto 33% in regards to the news.
Acadia Pharmaceuticals (ACAD) notched a win in a patent battle Wednesday pertaining to its Parkinson's drug, Nuplazid. ACAD stock soared to a four-month high.
ACAD Stock: Cashing In On...
NASDAQ:ACAD - expecting a turn 180 degree and beginning of the moddle-term long position.
NASDAQ:ACAD :: HKEX:18 -> HKEX:30 ::67%::Oct 2023
Does not constitute a recommendation.
#investing #stocks #idea #forecast #furoreggs
Please, subscribe and challenge my point of view )
A small channel up within a larger channel down
I expect a breakout up to the top of the larger down channel
This works well with a curved bowl recovery structure
ACADIA Pharmaceuticals Inc. has a significant catalyst event scheduled for March 12th, 2023. After a prolonged decline, the stock has rebounded and broken out of a downward trend, indicating potential for upward movement. Investors should keep an eye on this biotech company as it approaches the catalyst date. Additional information on biotech catalysts can be...
Beautiful tap of long term support could signal a large double bottom. If we can pop and close above 20$ could bring us to retest upper resiatnce of 25 or 27$. If we fail 20$ I would look for a retest or 16$ range huge buy volume came in at 16$ I wouldn’t chase this but keep on radar for a pull back
I had this mapped out but I misse the trade! Damn! What do I do!? We’ll I’ll tell you, I don’t come in here now and FOMO. I draw some fibs and look for previous resiatnce.
I see a lot o wicks and no candles closing above .382 from recent high to low of 21.07
This price is 22.48
I have some bids there. I see .618 at 22.14. This is also the low supprt of...
NASDAQ:ACAD .. I have been along with this one for a few months now. Around this price range is where we see big-time moves. This $21.88 level is a key level for this stock. It has been in a downtrend since it hit its 3 month high at the end of December. With how the market has been to begin this year, the downtrend seems more likely to continue. There is a good...
ACAD seems to me it finished the first wave of an A-B-C zig-zag pattern, we should expect now a 3 waves move to the upside with price not retracing more than 61,8% Fib . Correction might take us to 6,13$-3,53 $ range.
Good afternoon, Acadia Pharmaceuticals has been trading rangebound since 2013. There is RSI bullish divergence on the weekly timeframe and bull fisher divergence, powerful signals placed in the demand zone. Big swings on this a financial asset. NFA and always DYOR.
Possible Reversal trade:
After a huge gap (-40%) price approaching support level ($14.4)
Volume spikes during the last 6 months.
RSI growing (but still under 50)
Earning call 11/9
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The...
On March 9, the FDA identified flaws in ACADIA's application for a new drug for Pimavanserin to treat hallucinations and delusions associated with psychosis and dementia.
By April 3, Acadia is likely to receive a full response letter from the FDA.
DRP approval of Pimavanserin is unlikely, but possible.
The stock bounced off 24.00, then 26.00 and 27.00. The figure...
Long fall after a disappointing study result, I think? Earnings May 26th.
Triple top noted but has fallen more than this structure would measure.
No recommendation
Sometimes when stocks gap down, price goes up only to fall again (dead cat bounce) so always good to be sure the bottom is the bottom. Gaps down are bearish and even though this gap will most likely...
ACAD LONG SET UP, ACAD Gapped down over 25% to a New 52 week low.
Price should bounce and fill in the Gap in the market
ACAD also filled its previous Buy gap from Sep 4th 2019
Title: Buy ACAD (ACADIA Pharmaceuticals)
Asset: Stock
Platform: Robinhood/WeBull/Etrade/ 401k account
Symbol: ACAD
Type: Buy Market Execution / Buy Limit
Time Frame: 1D
Entry Price...
So what has caused such plummet? I've carried out a research and found out. 😀
Stock has declined due to the simple fact that FDA has requested the specific requirements for the drug labeling.
By the way, The drug (Pimavanserin) has already been approved by FDA for quite long time.
So in general, regulatory setback was in post-marketing requirements.
...
